Purpose: Gemcitabine (GEM) and vinorelbine (VNR) are both active against advanced breast cancer (ABC), being able to induce a median ORR of 25% and 40%, respectively. Because of their different mechanism of action and good tolerability, the combination of GEM and VNR has been tested in ABC.
Introduction
Despite progress achieved in pharmacological research, the prognosis of disseminated advanced breast cancer (ABC) still remains poor. Median duration of objective response (OR) and overall survival (OS) are usually less than 10 months and 18 months, respectively [1] . Consequently, many of these patients may still require salvage chemotherapy after aggressive first-line therapy.
Interesting clinical data have been recently reported with single-agent gemcitabine (GEM) and vinorelbine (VNR) in several human solid tumors [2, 3] . The combination of such drugs, which display good tolerability, different mechanisms of action, and similar weekly schedules of administration on an out-patient basis, might reppresent an interesting regimen for the palliative treatment of ABC. The feasibility, toxicity and activity of a GEM-VNR combination were tested in a series of anthracycline/taxane-pretreated ABC patients. 3s4000/mmc, PTL ^ 120,000/mmc, absence of cerebral metastases and active infections.
Treatment plan
Patients were treated on day 1,8 and 15 with GEM 1000 mg/m 2 diluted in 250 cc of normal saline given i.v. as 30 minute infusion, plus VNR 25 mg/m 2 given i.v. bolus on day 1 and 8, every 28 days. G-CSF 5 ug/kg s.c. was given as needed. In case of progressive disease (PD) chemotherapy was halted; if patients showed stable disease (SD) or major OR, chemotherapy was administered for up to 10 cycles.
Response, toxicity, statistics
Patients were evaluated for OR after two cycles with GEM and VNR, and every cycle for toxicity accordingly to standard WHO criteria [9] . Duration of OR and time to progression (TTP) were calculated from the date of registration until last follow-up, or date when PD was documented or death. OR rates were reported as relative rates with 95% confidence intervals (95% CI). Fisher's exact test was used to compare ORR in patient subgroups. The Kaplan-Meier product-limit method was used to estimate duration of OR, OS and TTP.
Patients and methodŝ legibility criteria
Elegibility criteria were: ethical committee approval; age ^ 70 years, ECOG PS ^2 , expected survival ^6 months, informed consent, measurable disease accordingly to WHO [4] ; good cardiac function, serum transaminases ^2 times normal value, serum bilirubin ^1.2 mg%, BUN $ 5 0 mg%, serum creatinine $1.2 mg%, and WBC
Results

Patient characteristics
The characteristics of enrolled patients are reported seen in 21% of patients, but only three (10%) experienced grade 3 toxicity. Anemia was infrequent, with only 6.8% of patients affected by grade 2 toxicity. The other non-hematological toxicities were as follows: asthenia recorded in 14% of patients, increase in serum transaminases in 10% (grade 1 in 7% and grade 2 in 3% of cases), and grade 1 neurotoxicity in 10%.
Discussion
In several phase II studies on ABC patients single-agent GEM has yielded a 25%-46% ORR depending on type and extension of pretreatment [5, 6] . VNR has been shown to be a highly active agent in ABC with a 40%-45% ORR [2] . Although efficacy is higher in patients treated with VNR as first-line chemotherapy, significant antitumor activity has also been reported when employed as second-line therapy [2, 7] . The 48% ORR achieved in this study, although not yet satisfactory, is among the highest reported for second-line treatment of ABC [1, 8] .
Tolerance to the GEM-VNR combination was fairly good with leukopenia being the main hematologic toxicity.
In conclusion, the results of this pilot study suggest that GEM-VNR regimen is active as second-line chemotherapy for ABC even if pretreated with anthracycline and taxanes. Further studies with a larger number of patients are required to confirm these results. 
Response and survival
CR was observed in 3 out of 29 patients (10%, 95% CI: 2%-27%), PR was observed in 11 (38%, 95% CI: 21%-58%) for an ORR of 48% (95% CI: 29%-67%). There were also eight patients with SD (28%) with a mean duration of 5+ months (range 3+-9), and seven with PD (24%). The mean duration of CR and PR were 11 + (range 4+-18) and 9.5+ (range 4+-15) months, respectively. SD lasted a mean of 5+ months (range 3+-9). After a mean follow-up of 9.25 months, median OS has not yet been reached since only one-third of the patients have died to date. Mean OS was 15.1+ months for CR patients (range 6+-21), 10.2+ months for PR (range 4+-15+), 8.3+ for SD (range 3+-10+), and 5.8+ for PD (range 3-8). Overall mean TTP and OS for all patients were 6.8+ months and 9.2+ months, respectively.
Toxicity
Enrolled patients received a total of 145 cycles with a mean of 5 cycles /patients (range 2-10). Leukopenia was the most frequent and severe adverse effect: 18 of 29 patients (48%) experienced grade 3 leukopenia without episodes of neutropenic fever. Thrombocytopenia was
